Scholarlink

<p>Immune checkpoint inhibitors (ICIs) are successfully used in multiple malignant diseases. Their spectrum of adverse effects includes dermatological, endocrinological, gastrointestinal, and hepatic toxicities, as well as rare neurological side effects affecting the central nervous system and more frequently the peripheral nervous system. Pre-existing neurological disorders may deteriorate. Bilateral carpal tunnel syndrome (CTS) rarely occurs. In the present case, an 83-year-old patient with stage IIIC malignant melanoma (MM) developed pain, swelling, and paresthesia in both hands after five adjuvant therapy cycles with pembrolizumab 200&#xa0;mg. Following the diagnosis of bilateral CTS, pulse therapy with prednisolone was initiated and subsequently reduced to a maintenance dose of 20&#xa0;mg orally. Despite the necessary escalation of ICI therapy to ipilimumab/nivolumab due to MM progression, CTS improved under concomitant prednisolone therapy and physiotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bilaterales Karpaltunnelsyndrom bei einem Patienten mit malignem Melanom unter adjuvanter Pembrolizumab-Therapie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月2日

查看全文
  • S. Weyer-Fahlbusch,
  • M. Sandersfeld,
  • C. Ritthaler,
  • L. Hauck,
  • P. Dücker,
  • L. Susok,
  • T. Gambichler

摘要

Immune checkpoint inhibitors (ICIs) are successfully used in multiple malignant diseases. Their spectrum of adverse effects includes dermatological, endocrinological, gastrointestinal, and hepatic toxicities, as well as rare neurological side effects affecting the central nervous system and more frequently the peripheral nervous system. Pre-existing neurological disorders may deteriorate. Bilateral carpal tunnel syndrome (CTS) rarely occurs. In the present case, an 83-year-old patient with stage IIIC malignant melanoma (MM) developed pain, swelling, and paresthesia in both hands after five adjuvant therapy cycles with pembrolizumab 200 mg. Following the diagnosis of bilateral CTS, pulse therapy with prednisolone was initiated and subsequently reduced to a maintenance dose of 20 mg orally. Despite the necessary escalation of ICI therapy to ipilimumab/nivolumab due to MM progression, CTS improved under concomitant prednisolone therapy and physiotherapy.